Brandywine Global Investment Management LLC bought a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,619,764 shares of the company's stock, valued at approximately $33,804,000. Brandywine Global Investment Management LLC owned about 0.24% of Genmab A/S at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of the business. NEOS Investment Management LLC boosted its stake in Genmab A/S by 91.2% in the fourth quarter. NEOS Investment Management LLC now owns 78,683 shares of the company's stock valued at $1,642,000 after acquiring an additional 37,533 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Genmab A/S by 3,049.3% during the 4th quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company's stock worth $8,507,000 after buying an additional 394,670 shares during the period. LPL Financial LLC raised its holdings in shares of Genmab A/S by 3.3% during the fourth quarter. LPL Financial LLC now owns 195,436 shares of the company's stock worth $4,079,000 after acquiring an additional 6,288 shares during the period. Sei Investments Co. increased its holdings in Genmab A/S by 55.2% during the 4th quarter. Sei Investments Co. now owns 57,702 shares of the company's stock worth $1,205,000 after purchasing an additional 20,525 shares in the last quarter. Finally, Signaturefd LLC raised its stake in shares of Genmab A/S by 163.2% in the 4th quarter. Signaturefd LLC now owns 20,790 shares of the company's stock valued at $434,000 after purchasing an additional 12,890 shares during the period. Institutional investors and hedge funds own 7.07% of the company's stock.
Genmab A/S Stock Performance
Shares of GMAB stock traded up $0.43 during trading on Thursday, hitting $19.25. The company had a trading volume of 966,637 shares, compared to its average volume of 1,502,117. The firm has a market capitalization of $12.74 billion, a P/E ratio of 11.06, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. Genmab A/S has a one year low of $18.48 and a one year high of $30.50. The stock's 50-day moving average price is $20.76 and its 200 day moving average price is $21.71.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, research analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on GMAB. Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target for the company in a research report on Thursday, February 13th. Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Finally, Truist Financial dropped their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $41.33.
View Our Latest Research Report on GMAB
About Genmab A/S
(
Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
